AMRX
HealthcareAmneal Pharmaceuticals, Inc.
$12.71
+$0.05 (+0.39%)
Jan 5, 2026
Price History (1Y)
Analysis
Amneal Pharmaceuticals, Inc. is a healthcare company operating in the specialty and generic drug manufacturing industry. With a market capitalization of $4.00 billion, the company's scale is significant, employing approximately 8,300 individuals. Its sector and industry classification provide context for its business operations. The company's financial health indicates moderate profitability, with gross margin at 37.3% and operating margin at 11.9%. However, profit margin stands at a relatively low 0.2%, suggesting that the company may face challenges in converting revenue into net income. From an asset utilization perspective, return on assets (ROA) is reported to be 6.8%. The balance sheet shows a substantial debt level of $2.69 billion, although this is partially offset by cash holdings of $203.48 million. Amneal Pharmaceuticals' valuation metrics reveal mixed signals. With a P/E ratio of 1271.00 (TTM) and forward P/E of 13.72, the company's current price-to-earnings multiple is notably high compared to its expected earnings growth. Revenue has grown by 11.7% year-over-year, providing some indication of underlying business performance.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Visit website →Key Statistics
- Market Cap
- $4.00B
- P/E Ratio
- 1271.00
- 52-Week High
- $13.01
- 52-Week Low
- $6.68
- Avg Volume
- 1.75M
- Beta
- 1.35
Company Info
- Exchange
- NMS
- Country
- United States
- Employees
- 8,300